General Information of Drug (ID: DM8LG2I)

Drug Name
AF-130 Drug Info
Indication
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM8LG2I

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug(s) Targeting P2X purinoceptor 3 (P2RX3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gefapixant DM4GWL7 Cough MD12 Phase 3 [2]
BAY-1902607 DMYSQMW Cough MD12 Phase 2 [2]
BAY 1902607 DMFA4CK Cough MD12 Phase 1/2 [2]
BAY-1817080 DMNL5G7 Endometriosis GA10 Phase 1 [2]
BAY 1817080 DMF9ALP Cough MD12 Phase 1 [3]
BzATP DM37GYA Discovery agent N.A. Investigative [4]
TNP-ATP DMVZY0X Discovery agent N.A. Investigative [5]
ISOPPADS DMWI0M8 Discovery agent N.A. Investigative [6]
LVAYPWT DMIO405 Discovery agent N.A. Investigative [7]
MK-3901 DM5EQ7F Pain MG30-MG3Z Investigative [4]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
P2X purinoceptor 3 (P2RX3) TT2THBD P2RX3_HUMAN Antagonist [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
3 Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J. 2021 May 13;2004240.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 480).
5 Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors. Mol Pharmacol. 1998 Jun;53(6):969-73.
6 Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors. J Med Chem. 2001 Feb 1;44(3):340-9.
7 Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. J Med Chem. 2007 Sep 6;50(18):4543-7.